The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma
On June 24, 2022, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lisocabtagene maraleucel (liso-cel, Breyanzi), a chimeric antigen receptor (CAR) T cell therapy, for adult patients with large B-cell lymphoma (LBCL) who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. It is not indicated for the treatment of patients with primary central nervous system lymphoma.
“DLBCL is the most common type of lymphoma, and while our investment in research has improved outcomes for many, patients with relapsed or refractory disease face important decisions for second-line therapy,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Lisocabtagene maraleucel is an innovative treatment that offers a new option for these patients, and another reason for this community to maintain hope for the future.”
Learn About: Immunotherapy
The term “immunotherapy” (also called immune-oncology) refers to treatments that interact with the immune system. The purpose of the immune system is to eliminate harmful pathogens, like bacteria and viruses, as well as cancer cells from the body. However, in many cancers, including lymphoma, the immune system doesn’t work properly, which allows the cancer cells to grow and spread.